Frexalimab

Last updated

Frexalimab
Monoclonal antibody
Type Whole antibody
Target CD40 ligand
Clinical data
AHFS/Drugs.com Monograph
License data
Legal status
Legal status
  • Investigational
Identifiers
PubChem SID
ChemSpider
  • none
KEGG

Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis. [1] [2] [3] [4] [5] [6]

References

  1. Carvalho, Thiago (5 July 2023). "Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis" . Nature Medicine. 29 (8): 1882–1883. doi:10.1038/d41591-023-00060-4. PMID   37407835.
  2. Niebel, Dennis; de Vos, Luka; Fetter, Tanja; Brägelmann, Christine; Wenzel, Jörg (July 2023). "Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions". American Journal of Clinical Dermatology. 24 (4): 521–540. doi: 10.1007/s40257-023-00774-8 . PMC   10157137 . PMID   37140884.
  3. Ritter, Jacob; Chen, Yidan; Stefanski, Ana-Luisa; Dörner, Thomas (November 2022). "Current and future treatment in primary Sjögren's syndrome – A still challenging development". Joint Bone Spine. 89 (6): 105406. doi:10.1016/j.jbspin.2022.105406. PMID   35537697.
  4. Fadul, Camilo E.; Mao-Draayer, Yang; Ryan, Kathleen A.; Noelle, Randolph J.; Wishart, Heather A.; Channon, Jacqueline Y.; Kasper, Isaac R.; Oliver, Brant; Mielcarz, Daniel W.; Kasper, Lloyd H. (November 2021). "Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis". Neurology: Neuroimmunology & Neuroinflammation. 8 (6): e1096. doi: 10.1212/NXI.0000000000001096 . PMC   8527364 . PMID   34654708.
  5. Vial, G.; Gensous, N.; Duffau, P. (October 2021). "L'axe CD40-CD40L : implications actuelles et futures en immunologie clinique". La Revue de Médecine Interne. 42 (10): 722–728. doi: 10.1016/j.revmed.2021.02.005 . PMID   33674076.
  6. Cree, Bruce A.C.; Hartung, Hans-Peter; Barnett, Michael (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Current Opinion in Neurology. 35 (3): 262–270. doi: 10.1097/WCO.0000000000001063 . PMID   35674067.